JP2021529792A5 - - Google Patents

Info

Publication number
JP2021529792A5
JP2021529792A5 JP2020573524A JP2020573524A JP2021529792A5 JP 2021529792 A5 JP2021529792 A5 JP 2021529792A5 JP 2020573524 A JP2020573524 A JP 2020573524A JP 2020573524 A JP2020573524 A JP 2020573524A JP 2021529792 A5 JP2021529792 A5 JP 2021529792A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
hydrogen
clathrate
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020573524A
Other languages
English (en)
Japanese (ja)
Other versions
JP7561632B2 (ja
JP2021529792A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039600 external-priority patent/WO2020006296A1/en
Publication of JP2021529792A publication Critical patent/JP2021529792A/ja
Publication of JP2021529792A5 publication Critical patent/JP2021529792A5/ja
Priority to JP2024094936A priority Critical patent/JP2024138260A/ja
Application granted granted Critical
Publication of JP7561632B2 publication Critical patent/JP7561632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573524A 2018-06-27 2019-06-27 プロテアソーム活性増強化合物 Active JP7561632B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094936A JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690563P 2018-06-27 2018-06-27
US201862690565P 2018-06-27 2018-06-27
US62/690,565 2018-06-27
US62/690,563 2018-06-27
PCT/US2019/039600 WO2020006296A1 (en) 2018-06-27 2019-06-27 Proteasome activity enhancing compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094936A Division JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Publications (3)

Publication Number Publication Date
JP2021529792A JP2021529792A (ja) 2021-11-04
JP2021529792A5 true JP2021529792A5 (https=) 2022-06-29
JP7561632B2 JP7561632B2 (ja) 2024-10-04

Family

ID=67439356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573524A Active JP7561632B2 (ja) 2018-06-27 2019-06-27 プロテアソーム活性増強化合物
JP2024094936A Withdrawn JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094936A Withdrawn JP2024138260A (ja) 2018-06-27 2024-06-12 プロテアソーム活性増強化合物

Country Status (17)

Country Link
US (2) US11560385B2 (https=)
EP (1) EP3814338A1 (https=)
JP (2) JP7561632B2 (https=)
KR (1) KR20210024588A (https=)
CN (1) CN112585132B (https=)
AU (1) AU2019295765B2 (https=)
BR (2) BR112020026580A2 (https=)
CA (1) CA3103954A1 (https=)
CL (1) CL2020003380A1 (https=)
CR (1) CR20200652A (https=)
IL (1) IL279698A (https=)
MA (1) MA53014A (https=)
MX (1) MX2020014082A (https=)
PE (1) PE20211804A1 (https=)
PH (1) PH12020552261A1 (https=)
SG (1) SG11202013026WA (https=)
WO (1) WO2020006296A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102767739B1 (ko) 2018-06-27 2025-02-12 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
CN111423353B (zh) * 2020-04-29 2022-03-22 湖北省生物农药工程研究中心 多取代n-芳基吡咯类化合物及其制备方法
CN112142642B (zh) * 2020-10-15 2022-03-04 华侨大学 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法
WO2023107597A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Bicyclic heteroaromatic amide compounds and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1142508A (en) 1966-04-27 1969-02-12 Whitefin Holding Sa Pyrrole derivatives
GB1154744A (en) 1966-05-17 1969-06-11 Whitefin Holding Sa Disubstituted Aminoethanols
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
BR9907228A (pt) 1998-01-23 2000-10-24 Nat Jewish Med & Res Center Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
US20060148767A1 (en) 2001-12-06 2006-07-06 George Cioca Use of acyl salicylates as heat shock inducers
CA2545433A1 (en) 2003-11-12 2005-05-26 Amicus Therapeutics Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
AU2006254796B2 (en) 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
US20070207992A1 (en) 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
WO2007131034A1 (en) 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
PL2533050T6 (pl) 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
PL1860101T3 (pl) 2006-05-24 2011-10-31 Amicus Therapeutics Inc Sól winianu izofagominy i sposoby zastosowania
WO2007150064A2 (en) 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
AU2009228765B2 (en) 2008-03-24 2012-05-31 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
KR20120117905A (ko) * 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
HUE044867T2 (hu) 2011-05-12 2019-11-28 Proteostasis Therapeutics Inc Proteosztázis szabályzók
US9849135B2 (en) * 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Similar Documents

Publication Publication Date Title
JP2021529792A5 (https=)
JP2016531121A5 (https=)
JP2017132814A5 (https=)
JP2015522650A5 (https=)
JP2013531029A5 (https=)
JP2015527387A5 (https=)
AR082218A1 (es) Derivados de arilamida que tienen propiedades antiandrogenicas y proceso de preparacion
JP2017119663A5 (https=)
JP2017506666A5 (https=)
RU2016125306A (ru) Новые пестицидные соединения и применения
JP2017503833A5 (https=)
JP2009511490A5 (https=)
JP2009515988A5 (https=)
JP2016506962A5 (https=)
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
JP2016505614A5 (https=)
RU2019130519A (ru) 4-пиридоновое соединение или его соль, фармацевтическая композиция и содержащий их состав
JP2024532768A5 (https=)
RU2016118399A (ru) Производные 4-аминометилбензойной кислоты
JP2016531126A5 (https=)
JP2019529419A5 (https=)
MX395406B (es) Compuestos de piperidinobenzodiazepina con actividad antiproliferativa.
JP2015535847A5 (https=)
JP2016503778A5 (https=)
JP2006508979A5 (https=)